Sign in
4

Changes in Ownership

Fulcrum Therapeutics, Inc. Filed Acc 0000899243-23-004745

Options or other derivatives

  • Chief Legal Officer acquired 150,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Oltmans Curtis Gale Chief Legal Officer 2023-02-09 Grant or award · Stock Option (right to buy) +150,000 150,000 D
Loading xslF345X03/doc4.xml…